Wie hoch ist der Preis für Gilead Sciences, Inc. (GILD)

Preis für Gilead Sciences, Inc. (GILD) ist $150.78

Wie hoch ist die Marktkapitalisierung für Gilead Sciences, Inc. (GILD)

Marktkapitalisierung für Gilead Sciences, Inc. (GILD) ist $187.20B

Gilead Sciences, Inc. (GILD) Aktiensplits

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Jahr	Aktien-Split	Multiplikator	Kumulierter Multiplikator
2013-01-28	2:1	x2	x32
2007-06-25	2:1	x2	x16
2004-09-07	2:1	x2	x8
2002-03-08	2:1	x2	x4
2001-02-22	2:1	x2	x2

Jahr

Aktien-Split

Multiplikator

Kumulierter Multiplikator

2013-01-28

2:1

x32

2007-06-25

2:1

x16

2004-09-07

2:1

2002-03-08

2:1

2001-02-22

2:1

Unternehmen	Anzahl der Aktiensplits	Kumulierter Multiplikator	Land
Eli Lilly and Company LLY.US	4	x15	US
Johnson & Johnson JNJ.US	7	x432	US
AbbVie Inc. ABBV.US	0	-	US
Roche Holding AG RO.SW	2	x10000	CH
Merck & Co., Inc. MRK.US	7	x226	US

Unternehmen

Anzahl der Aktiensplits

Kumulierter Multiplikator

Land